Please login to the form below

Not currently logged in
Email:
Password:

ledipasvir/sofosbuvir

This page shows the latest ledipasvir/sofosbuvir news and features for those working in and with pharma, biotech and healthcare.

Merck & Co pulls out of hepatitis C R&D as market shrinks

Merck & Co pulls out of hepatitis C R&D as market shrinks

In the same period, Gilead’s HCV portfolio of Harvoni (sofosbuvir/ledipasvir), Epclusa (sofosbuvir/velpatasvir) and Sovaldi (sofosbuvir) brought in $5.44bn, down from around $8.3bn in the first half

Latest news

More from news
Approximately 1 fully matching, plus 49 partially matching documents found.

Latest Intelligence

  • AbbVie: New firm, new thinking AbbVie: New firm, new thinking

    Gilead Sciences has emerged as the leader in this field with Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir), both of which have already made billions of dollars.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics